SB 209509: Began Phase II dose-ranging trial of the oral compound in 50 patients.

Vanguard Medica, Guildford, U.K. Product: SB 209509, 5HT1D receptor partial agonist Indication: Migraine Status: Began Phase II dose-ranging trial of the oral compound in 50 patients. SB 209509 is be...